Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
NCT07021963Phase 2Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Suncadia Medicine Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07021963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021963.